Yesterday, Novo Nordisk received top placement in the Dow Jones Sustainability Index (DJSI) and the Carbon Disclosure Project (CDP), two of the most influential rankings of sustainability performance and disclosure by private companies. The company achieved 85 points in the DJSI compared to 86 points in 2012. The pharmaceutical sector has an average score of 47 in the index. In the CDP, Novo Nordisk’s carbon disclosure efforts placed the company in the top 6, improving its score by 6 points to 96 points.

“Global sustainability rankings are valuable for us as guiding indicators of where, in the eyes of the raters, we can improve. They also provide transparent insight to our stakeholders who want to see how well we are doing towards creating long-term, sustainable value,” says Susanne Stormer, vice president, Corporate Sustainability, Novo Nordisk.

In the past year, Novo Nordisk has received top recognition in both global and industry specific sustainability rankings. The company was ranked 6th in the Access to Medicine Index (November 2012) and 5th in the Global 100 index by Corporate Knights (January 2013).

“We are proud to be among the top performers globally and in the healthcare sector. However, such benchmarks also spur us and our peers to stretch for excellence. So each year we carefully review the results and identify the areas where we want to make an extra effort to improve performance and disclosure,” says Stormer.

In the DJSI, Novo Nordisk achieved best score for the pharmaceutical industry in five categories – Environmental Policy/Management System, Bioethics, Human Capital Development, Health Outcome Contribution, and Social Reporting. The highest increase in scores was found in the categories of Innovation Management, Human Capital Development and Health Outcome Contribution.

Both indices are investor-led and are intended to serve as benchmarks for investors who integrate sustainability considerations into their portfolios and look for best-in-class performance. The Dow Jones Sustainability Index tracks the world’s leading companies in terms of their social, environmental and economic performance The Carbon Disclosure Project is an annual ranking of how well the global 500 largest companies manage climate change risks and opportunities and how well they mitigate their impact.

Read more about Novo Nordisk's sustainability work.

Dow Jones Sustainability Index
Read more about the Dow Jones Sustainability Index.

Carbon Disclosure Project
The full Carbon Disclosure Project Global 500 report can be downloaded from www.cdproject.net.

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk